BACKGROUND The USA 2004 influenza virus outbreak H3N8 in dogs heralded the emergence of a new disease in this species. A new inactivated H3N8 vaccine was developed to control the spread of the disease but, as in humans and swine, it is anticipated that the virus will mutate shift and drift in the dog population. Therefore, there is a need for a vaccine that can trigger a broad protection to pre...

Whole-virus vaccines, including inactivated or live-attenuated influenza vaccines, have been conventionally developed and supported as a prophylaxis. These currently available virus-based influenza vaccines are widely used in the clinic, but the vaccine production takes a long time and a huge number of embryonated chicken eggs. To overcome the imperfection of egg-based influenza vaccines, epito...

e14563 Background: Tumor-specific neoantigens are considered as personalized and potential ultimate targets for cancer immunotherapy. Recently, neoantigen vaccines have been designed to train the patient's immune system specifically target kill tumor cells. However, safety efficacy of in pancreatic treatment remain poorly understood. Methods: Personalized peptide were successfully manufactured ...

Carcinoembryonic antigen glypican-3 (GPC3) is expressed by>40% of ovarian clear cell carcinoma (CCC) and is a promising immunotherapeutic target. We previously reported the safety of and immunological and clinical responses to a GPC3-derived peptide vaccine in a phase I clinical trial of patients with advanced hepatocellular carcinoma (HCC). Although the efficacy of the GPC3-derived peptide vac...

The identification of human Wilms' tumor gene 1 (WT1) protein-derived cytotoxic T lymphocyte (CTL) epitopes and the in vivo efficacy of WT1 peptide-based immunotherapy in a mouse model were reported in 2000. This successful basic research led to clinical studies of a WT1 peptide vaccine, and a positive impact on clinical response was first demonstrated in 2003 in the form of a reduction in blas...

1. Abstract 2. Introduction 3. Stress protein families and their immunological properties 3.1. Chaperoning properties 3.2. Peptide binding properties 3.3. Hsps interact with APCs 4. Immunogenicity of hsps 4.1. Tumor-derived hsp vaccines 4.2. Hsp-peptide based vaccines 4.3. Hsp-protein based vaccines 4.4. Hsp-based DNA vaccines 4.5. Hsp fusion protein vaccines 4.6. Cell-based vaccines 5. Improve...

PURPOSE The clinical efficacy of cancer peptide vaccine therapy is insufficient. To enhance the anti-tumor effect of peptide vaccine therapy, we combined this therapy with an anti-CD4 mAb (GK1.5), which is known to deplete CD4+ cells, including regulatory T cells (Tregs). METHODS To determine the treatment schedule, the number of lymphocyte subsets in the peripheral blood of mice was traced b...